Founded in 2009, Aminex was an early company to recognize the potential benefits of combination drug therapy in immunotherapy. Today, combination therapy is developing rapidly and demonstrating promising results. Some of oncology’s most respected thought leaders are beginning to predict significantly improved outcomes for certain cancers based on advances in this field.

From its inception, Aminex recognized the partial cancer treatment benefits of a now off-patent drug, DFMO (eflornithine), developed more than 30 years ago. As an approved treatment for African sleeping sickness, DFMO has been credited for having saved more than 100,000 lives. Our goal was to develop a companion drug to address the deficiencies that prevented DFMO from being approved for cancer treatment. Aminex finalized development of the companion drug, AMXT-1501, with the goal of demonstrating the cancer therapy benefits of the two-drug combination, identified as AMXT 1501/DFMO.


AMXT 1501/DFMO belongs to a subclass of cancer immunotherapies known as suppressor cell modulators (SCMs). It has the potential to be a transformative immunotherapy treatment for several cancer types, both as an independent treatment and in combination with other immunotherapy drugs. Additionally, AMXT 1501/DFMO’s small molecule design and low chemical production costs will allow substantial pricing flexibility compared to the pricing of current biologics and cell therapy treatments.


Aminex has a small, focused organization. The following sections contain the biographical summaries of its Directors, Management and Scientific Advisory Board members. It is a strong, exceptionally experienced team.